Amarin Corporation

Amarin Corporation FCF Margin

The Free Cash Flow Margin of Amarin Corporation (AMRN) as of Nov 19, 2026 is 3.16 %. In the previous year, Free Cash Flow Margin was -13.57 % — a change of -123.26% (higher).

FCF Margin

3.16 %

YoY

-123.26%

Last updated:

Free Cash Flow Margin of Amarin Corporation is 2025 3.16 % . Free Cash Flow Margin of Amarin Corporation was 2024 -13.57 % . It decreases by -123.26% higher compared to the previous year.

The Amarin Corporation FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
-41.34 USD
Jan 1, 2019
-2.76 USD
Jan 1, 2020
-3.58 USD
Jan 1, 2021
-11.41 USD
Jan 1, 2022
-48.75 USD
Jan 1, 2023
2.24 USD
Jan 1, 2024
-13.57 USD
Jan 1, 2025
3.16 USD
The Amarin Corporation FCF Margin history
YEARFCF MarginYoY
3.16 %-123.26%
-13.57 %-705.06%
2.24 %-104.60%
-48.75 %+327.34%
-11.41 %+218.44%
-3.58 %+29.99%
-2.76 %-93.33%
-41.34 %+127.93%
-18.14 %-67.15%
-55.22 %-46.74%
-103.69 %-22.30%
-133.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amarin Corporation Stock analysis

What does Amarin Corporation do? Amarin Corporation PLC generates revenue primarily through the sale of Vascepa (icosapent ethyl) capsules, approved by the FDA for reducing triglyceride levels in patients with severe hypertriglyceridemia. The company sells Vascepa to wholesalers, regional wholesalers, and specialty pharmacy providers, collectively referred to as distributors, who then resell the product to retail pharmacies for patient and healthcare provider use. The MARINE indication, derived from the MARINE study, is the key approved use driving sales in the cardiovascular health segment. Amarin's commercial strategy centers on the Vascepa segment, focusing on the development and commercialization of this therapeutic. The firm's lead product, Vascepa, is positioned as an adjunct to diet for treating severe hypertriglyceridemia, targeting healthcare providers and patients through a distribution network of wholesalers and specialty pharmacies. This model ensures Vascepa reaches retail pharmacies where it is dispensed to end users. Amarin Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Amarin Corporation stock

Free Cash Flow Margin of Amarin Corporation is 3.16 % in 2025.

Free Cash Flow Margin of Amarin Corporation changed from -13.57 % to 3.16 %, representing a -123.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Amarin Corporation since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Amarin Corporation with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Amarin Corporation

All Key Metrics — Amarin Corporation